Stock Worth Mentioning Today: After Today’s Huge Increase, Is Concordia International Corp’s Near-Term Analysis Positive?

Stock Worth Mentioning Today: After Today's Huge Increase, Is Concordia International Corp's Near Term Analysis Positive?

The stock of Concordia International Corp (NASDAQ:CXRX) is a huge mover today! About 1.17 million shares traded hands. Concordia International Corp (NASDAQ:CXRX) has declined 87.03% since April 14, 2016 and is downtrending. It has underperformed by 91.72% the S&P500.
The move comes after 7 months positive chart setup for the $159.68 million company. It was reported on Nov, 16 by Barchart.com. We have $8.71 PT which if reached, will make NASDAQ:CXRX worth $261.88 million more.

Concordia International Corp (NASDAQ:CXRX) Ratings Coverage

Out of 9 analysts covering Concordia Healthcare Corp. (NASDAQ:CXRX), 5 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 56% are positive. Concordia Healthcare Corp. has been the topic of 18 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The firm has “Hold” rating by GMP Securities given on Monday, August 15. The rating was maintained by Scotia Capital with “Sector Outperform” on Tuesday, September 29. The company was upgraded on Monday, September 19 by Scotia Capital. The firm has “Underperformer” rating given on Monday, August 15 by IBC. The rating was downgraded by TD Securities to “Hold” on Thursday, August 4. The rating was initiated by Goldman Sachs with “Neutral” on Monday, June 6. The stock has “Speculative Buy” rating given by Mackie on Monday, October 19. The stock of Concordia International Corp (NASDAQ:CXRX) earned “Buy” rating by Canaccord Genuity on Tuesday, August 11. Scotia Capital maintained it with “Sector Outperform” rating and $75 target price in Friday, October 16 report. The firm has “Buy” rating given on Friday, October 16 by S&P Research.

According to Zacks Investment Research, “Concordia International Corp is a diverse pharmaceutical company which focused on legacy pharmaceutical products and orphan drugs. The company also markets orphan drugs through its Orphan Drug Division, currently consisting of Photofrin(R) for the treatment of certain rare forms of cancer, which is currently undergoing testing for potential new indications. Concordia International Corp, formerly known as Concordia Healthcare Corp, is headquartered in Oakville, Canada.”

Another recent and important Concordia International Corp (NASDAQ:CXRX) news was published by Prnewswire.com which published an article titled: “Concordia International Corp. Announces CEO Transition Plan” on October 21, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment